AgomAb Therapeutics (NASDAQ:AGMB) Coverage Initiated at JPMorgan Chase & Co.

Analysts at JPMorgan Chase & Co. began coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a report issued on Tuesday, Marketbeat reports. The firm set an “overweight” rating and a $32.00 price target on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 117.98% from the stock’s previous close.

A number of other equities research analysts have also recently commented on AGMB. Morgan Stanley assumed coverage on AgomAb Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $28.00 price objective for the company. Wall Street Zen upgraded AgomAb Therapeutics to a “hold” rating in a report on Tuesday, February 17th. Finally, Leerink Partners started coverage on shares of AgomAb Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $36.00 price target for the company. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $32.00.

AgomAb Therapeutics Stock Performance

NASDAQ AGMB opened at $14.68 on Tuesday. AgomAb Therapeutics has a one year low of $12.66 and a one year high of $17.45.

Key AgomAb Therapeutics News

Here are the key news stories impacting AgomAb Therapeutics this week:

• Positive Sentiment: Major brokerages initiated or reiterated bullish coverage with high price targets that imply large upside vs. the current price — JPMorgan started coverage at “Overweight” with a $32 PT (~+118%). JPMorgan Coverage
• Positive Sentiment: Leerink Partners initiated coverage at “Outperform” with a $36 price target (~+145%), which could attract momentum buying from institutional investors. Leerink Coverage (Benzinga) Leerink Coverage (Zacks)
• Positive Sentiment: Morgan Stanley initiated coverage at “Overweight” with a $28 price target (~+91%), reinforcing analyst-driven upside expectations across the sell-side. Morgan Stanley Coverage
• Neutral Sentiment: Short-interest reports posted large increases in “short interest” for early March, but the published figures are internally inconsistent (showing 0 shares and NaN changes); the data appears unreliable and provides no clear signal on actual short pressure. Investors should treat these short-interest entries with caution until corrected filings are available.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.